European Journal of Medicinal Chemistry p. 334 - 341 (2019)
Update date:2022-08-16
Topics:
Ji, Dezhong
Zhang, Lingzhi
Zhu, Qihua
Bai, Ying
Wu, Yaoyao
Xu, Yungen
Constitutive activation of MAPK (RAS/RAF/MEK/ERK) pathway is frequently observed in many tumors and thus has become an interesting therapeutic target for cancer therapy. Despite the successful development of BRAF and MEK inhibitors in clinic treatment, resistance often appears to re-enhance ERK1/2 signaling. Inspired by the central role of the ERK1/2 signaling cascade in cancer, we describe the scaffold-hopping generation of a series of isoindolin-1-one ERK1/2 inhibitors. Our new compounds could inhibit proliferation of KRAS and BRAF mutant cells lines at low nanomolar concentrations. Compound 22a possesses acceptable pharmacokinetic profiles and showed considerable in vivo antitumor efficacy in a HCT-116 xenograft model, providing a promising basis for further optimization towards clinical ERK1/2 inhibitors.
View Morewebsite:http://www.easchem.com
Contact:+86-731-89722861 89722891
Address:2/F-4/Bld Colorful Palace, No.605 Changsha Ave, Yuhua Area Changsha Hunan China.
Huaihua Baohua Biotechnology Co.,Ltd
website:http://www.baochengchem.com
Contact:86-519-82698291
Address:HouYang chemical development zone,Jintan,Jiangsu,China (213200)
Hebei Lead Bio-Chemicals Co., Ltd.
website:http://www.ldbiochem.com
Contact:+86-311-87826503
Address:481, Heping West Road, Shijiazhuang,China
Yicheng Goto Pharmaceuticals Co.,Ltd.
Contact:+86 710 3423122
Address:5th Floor,East Gate of Building #2,Servo-Industrial Park,1st Qilin Road,Xiangyang,Hubei,China
Goldwills Pharmaceuticals Co., Ltd.
Contact:0916-2237889 13991621155
Address:North Suburb of Hanzhong city, Shaanxi Province
Doi:10.1016/j.apcata.2012.06.020
(2012)Doi:10.1016/j.tetlet.2006.07.057
(2006)Doi:10.3109/14756366.2015.1016511
(2016)Doi:10.1021/acscatal.5b01113
(2015)Doi:10.1080/10286020.2013.837454
(2013)Doi:10.1016/j.ejmech.2018.01.094
(2018)